- Waldenström Macroglobulinemia
- Melanoma
- Bladder Cancer
- Brain Cancer
- Breast Cancer
- Childhood Cancers
- Gastric Cancer
- Gynecologic Cancer
- Head & Neck Cancer
- Immunotherapy
- Kidney Cancer
- Leukemia
- Liver Cancer
- Lung Cancer
- Lymphoma Cancer
- Mesothelioma
- MPN
- MDS
- Myeloma
- Prostate Cancer
- Rare Cancers
- Sarcoma
- Skin Cancer
- Testicular Cancer
- Thyroid Cancer
There Are Multiple Dynamic Biomarkers for Bladder Cancer
While there are a few common and well-known checkpoints for bladder cancer, there are also many more than PD-1, PD-L1 and CTLA-4.
When it comes to biomarkers used to determine treatment strategy in bladder cancer, there is more than PD-1, PD-L1 and CTLA-4, says Padmanee Sharma, M.D., Ph.D., Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center.
Researchers have not yet examined or reached a full understanding of all the possible checkpoints, especially since the targets — like the immune response in general – are very dynamic and change over time.
Retired Teacher Turns to Former Student for Innovative Bladder Cancer Care
August 24th 2023“I treat all of my patients like my friends and family,” said Dr. Ravi Munver of Hackensack University Medical Center, who first met Peter Kahan as his honors physics teacher more than 35 years ago.
Listen
Genetics May Predict Treatment Responses But Not Survival in Bladder Cancer
November 30th 2023Analysis of molecular subtypes of muscle-invasive bladder cancer can predict if a tumor is likely to respond to chemotherapy before surgery but is not associated with differences in survival.
Read More
